Key result
Nebivolol add-on therapy significantly improved left ventricular ejection fraction compared to placebo (6.51% vs 3.97% increase; p=0.027) in elderly patients with chronic heart failure.
Why the study?
Does nebivolol improve left ventricular ejection fraction in elderly patients (>65 years) with chronic heart failure (NYHA class II-IV, LVEF <= 35%)?
Population
260 elderly patients with chronic heart failure, NYHA class II-IV, and left ventricular ejection fraction <=…
Comparison
Nebivolol administered as add-on therapy for 8… vs Placebo (control group)
Design
RCT
Follow-up
8 months
Authors
Loading...
Supports nebivolol add-on in elderly HFrEF; extends beta-blocker evidence to patients >65 years.
RCT (n=260)
Does nebivolol improve left ventricular ejection fraction in elderly patients (>65 years) with chronic heart failure (NYHA class II-IV, LVEF <= 35%)?
Absolute Event Rate: 6.51% vs 3.97%
p-value: p=0.027
Nebivolol as add-on therapy significantly improves left ventricular ejection fraction in elderly patients with chronic heart failure and reduced ejection fraction over 8 months.
Édes et al. (2005) conducted an RCT in chronic heart failure (CHF) (n=260). nebivolol vs. placebo was evaluated on change in LVEF (p=0.027). Nebivolol add-on therapy significantly improved left ventricular ejection fraction compared to placebo (6.51% vs 3.97% increase; p=0.027) in elderly patients with chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: